{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:15:35Z","timestamp":1778944535968,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-063"],"award-info":[{"award-number":["2021-I2M-1-063"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ahj.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:29:24Z","timestamp":1752625764000},"page":"268-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design, and study protocol for a multicenter randomized controlled trial (SAFE-AF)"],"prefix":"10.1016","volume":"290","author":[{"given":"Jiawei","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2867-411X","authenticated-orcid":false,"given":"Lihui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-6492","authenticated-orcid":false,"given":"Zhe","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.07.011_bib0001","doi-asserted-by":"crossref","first-page":"euae195","DOI":"10.1093\/europace\/euae195","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021","volume":"26","author":"Cheng","year":"2024","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2025.07.011_bib0002","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.011_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.14-0321","article-title":"Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation","volume":"147","author":"Guo","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2025.07.011_bib0004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2881","article-title":"Risk factors associated with ischemic stroke in Japanese patients with nonvalvular atrial fibrillation","volume":"3","author":"Okumura","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2025.07.011_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0007","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.07.011_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ehjqcco\/qcab054","article-title":"Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry","volume":"9","author":"Guo","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.ahj.2025.07.011_bib0009","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1007\/s00277-024-05767-z","article-title":"A systematic review and meta-analysis of the morbidity of efficacy endpoints and bleeding events in elderly and young patients treated with the same dose rivaroxaban","volume":"103","author":"Ren","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0010","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1253\/circj.CJ-14-0344","article-title":"Inappropriate use of oral anticoagulants for patients with atrial fibrillation","volume":"78","author":"Akao","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2025.07.011_bib0011","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0012","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.07.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"Yu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.07.011_bib0014","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0015","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2025.07.011_bib0016","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0017","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2025.07.011_bib0018","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0019","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.011_bib0021","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.07.011_bib0022","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0023","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.21037\/jtd.2018.03.95","article-title":"Recent progress and market analysis of anticoagulant drugs","volume":"10","author":"Fan","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ahj.2025.07.011_bib0024","article-title":"Cost-effectiveness analysis of rivaroxaban in Chinese patients with stable cardiovascular disease","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","article-title":"Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation","volume":"31","author":"Friberg","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.07.011_bib0026","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.011_bib0027","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.011_bib0028","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41401-022-00892-9","article-title":"Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ahj.2025.07.011_bib0029","article-title":"A combined pharmacometrics analysis of biomarker distribution under treatment with standard- or low-dose rivaroxaban in real-world Chinese patients with nonvalvular atrial fibrillation","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics15020588","article-title":"Is a lower dose of Rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of Rivaroxaban","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ahj.2025.07.011_bib0031","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.amjmed.2024.02.005","article-title":"Comparative safety and effectiveness of reduced doses of direct acting oral anticoagulants for stroke prevention in atrial fibrillation","volume":"137","author":"Skj\u00f8th","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0032","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1253\/circj.CJ-20-1244","article-title":"Effectiveness and safety of rivaroxaban by general practitioners- a multicenter, prospective study in Japanese patients with non-valvular atrial fibrillation (GENERAL)","volume":"85","author":"Kusano","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2025.07.011_bib0033","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"Shimokawa","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.07.011_bib0034","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2025.07.011_bib0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2018.01.065","article-title":"Clinical events after interruption of anticoagulation in patients with atrial fibrillation: an analysis from the ENGAGE AF-TIMI 48 trial","volume":"257","author":"Cavallari","year":"2018","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2025.07.011_bib0036","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/a-2278-8769","article-title":"Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study","volume":"124","author":"Kang","year":"2024","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.ahj.2025.07.011_bib0037","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2269-1123","article-title":"Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects","volume":"124","author":"Kang","year":"2024","journal-title":"Thromb Haemost"},{"issue":"19","key":"10.1016\/j.ahj.2025.07.011_bib0038","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ahj.2025.07.011_bib0039","doi-asserted-by":"crossref","first-page":"euad288","DOI":"10.1093\/europace\/euad288","article-title":"Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies","volume":"25","author":"Chan","year":"2023","journal-title":"Europace"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325002200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325002200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:04:55Z","timestamp":1778943895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325002200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0002870325002200"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design, and study protocol for a multicenter randomized controlled trial (SAFE-AF)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}